VERAXA Biotech advances VXA-222 bispecific ADC program with OmniAb
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
July 27, 2026 7:00 AM EDTVXA-222 advances into next phase at VERAXA
ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; VERAXA or the "Company"), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222, following successful achievement of a key technical milestone in its alliance with... More



